14
DEC
2018

NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

Posted By :
Comments : Off
BETHESDA, Md., December 14, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the package transaction involving the Company’s UK property, which the Company announced earlier this week, closed today in the UK. The closing included the transaction elements previously announced: The funding of approximately...
Read More
11
DEC
2018

NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

Posted By :
Comments : Off
BETHESDA, Md., December 11, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into agreements with a large multi-national corporation for a package transaction involving the Company’s property located near Cambridge, UK.  Pursuant to these agreements, The Company will sell most of its UK...
Read More
19
NOV
2018

Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma

Posted By :
Comments : Off
Presented at Society for Neuro-Oncology Conference Data Continuing to Mature, Particularly Regarding Long Tail of Survival Curve BETHESDA, Md., November 19, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer were presented...
Read More
13
NOV
2018

NW Bio Announces $5 Million Bridge Funding

Posted By :
Comments : Off
Notes With 50% Warrants Exercisable at $0.35 Per Share BETHESDA, Md., November 13, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on November 7, 2018, it completed an aggregate financing of $5 million from long term angel investors. The notes have a one-year maturity, subject to the Company’s right to prepay the...
Read More
28
AUG
2018

NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit

Posted By :
Comments : Off
BETHESDA, Md., August 28, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio is presenting at 8:00 pm Wednesday evening, August 29, at the Immuno-Oncology Summit being held at the Seaport World Trade Center, 1 Seaport Boulevard in Boston, Massachusetts. The title...
Read More